phase ii study of the braf inhibitor, vemurafenib, in patients with relapsed or refractory hairy...
TRANSCRIPT
Phase II Study of the BRAF Inhibitor, Vemurafenib, in
Patients With Relapsed or Refractory
Hairy Cell Leukemia (NCT01711632 )
Martin S. Tallman, M.D. Leukemia Service
Memorial Sloan Kettering Cancer CenterNCT01711632 Weill Cornell Medical College
New York, NY
Limitations of Purine Analogs
• Induce high response rates in HCL, but 20-30% relapse
• May not be curative
• Limited treatment options for relapsed and/or refractory disease
• Rates and duration of CR decline with each subsequent line of therapy
Novel Strategies in HCL
• Immunotoxins: (BL22/HA22) (anti-CD22 + truncated pseudomonas exotoxin A)
• Monoclonal antibodies: Rituximab
• Purine analogs + Rituximab
• Bendamustine + Rituximab
• Small molecule inhibitors (Vemurafenib, PLX8394)
Small molecule inhibitors: Vemurafenib
Rationale for Targeting BRAF in HCL
• BRAF V600E mutation present in 100% of classical HCL; absent in other B cell lymphoid malignancies
• Re-appears at disease relapse
• Trigger for constitutive MEK and ERK activation
• Treatment of primary HCL cells with the BRAF inhibitor decrease pMEK and pERK
• Vemurafenib is an effective and selective BRAF inhibitor, administered orally
Vemurafenib in a Patient With Refractory HCL
Peripheral blood counts prior to and post-treatment with vemurafenib
• Vemurafenib
• Within 2 days of treatment, spleen started to decrease and WBC & PLT counts increased
• By day 43, CR achieved as assessed by BMB
Dietrich et al. NEJM, 2012; Dietrich et al. J Clin Oncol, 2013
Participating Institutions
• Memorial Sloan-Kettering Cancer Center (Open)
• North Shore-LIJ Health System (Open)
• Dana-Farber Cancer Institute (Open)
• Scripps Clinic (Open)
• Northwestern University ( will open in May)
• Ohio State University (Open)
Key Eligibility Criteria
• Classical HCL with one of the following:– Intolerance to purine analogs – Failure to achieve any response (CR or PR)
to the initial purine analog-based therapy– Relapse ≤ 2 years of purine analog-based
therapy–≥ 2 relapses
• In need of therapy
– ANC ≤1.0, Hgb ≤10.0, or PLT ≤100K
• QTc < 480msc
Study Objectives
• Primary Objective– To determine the efficacy as assessed by ORR
• Secondary Objectives – To assess the safety and tolerability– To assess time to response, duration of
response, and MRD kinetics – To determine PFS and OS – To assess the PD via measurement of BRAF
downstream targets
Treatment Plan
Starting dose: Vemurafenib 960mg orally twice daily MRD assessed by immunohistochemistry
Acknowledgements
Jae Park, M.D.
Omar Abdel-Wahab, M.D.
Stephen Chung, M.D.